Flow Cytometric Examination Reveals Vimentin and CD44 Are Co-expressed with CD133 in a Small Subpopulation for all three of the Metastasis-Derived Prostate Cancer Cell Lines. This evidence concerns the gene CD44 and prostate carcinoma.